TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Synbiotics on Morbidity and Mortality in Preterm Infants
Brief Summary: Study, the inclusion of very low birth weight premature infants followed in Dr.Sami Ulus Maternity and Children Training and Research Hospital, Department of Neonatology; be randomized to very low birth weight premature infants began eating until you are discharged from the hospital once a day to feed a group+ 900 mg of 5 billion active Bifidobacterium lactis, the addition of chicory inulin, in the other group given placebo; Patients taking weekly blood cultures, the presence of residues in both groups during feeding, to evaluate the incidence of NEC and sepsis are planned. Randomization and the number of patients planned to separate into groups.


Options:
A: Arm Label: probiotics group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: probiotics | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: glucose solution | Intervention Type: DIETARY_SUPPLEMENT; Name: probiotics; Assigned to Arm(s): probiotics group | Intervention Type: DIETARY_SUPPLEMENT; Name: glucose solution; Assigned to Arm(s): control group
B: Arm Label: Bifidobacterium lactis; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium lactis plus İnülin, Other: Maltodextrin, Dietary Supplement: İnulin | Arm Label: İnulin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium lactis, Dietary Supplement: Bifidobacterium lactis plus İnülin, Other: Maltodextrin | Arm Label: Maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium lactis, Dietary Supplement: Bifidobacterium lactis plus İnülin, Dietary Supplement: İnulin | Arm Label: Bifidobacterium lactis plus İnülin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium lactis, Other: Maltodextrin, Dietary Supplement: İnulin | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium lactis; Assigned to Arm(s): Bifidobacterium lactis plus İnülin, Maltodextrin, İnulin | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium lactis plus İnülin; Assigned to Arm(s): Bifidobacterium lactis, Maltodextrin, İnulin | Intervention Type: OTHER; Name: Maltodextrin; Assigned to Arm(s): Bifidobacterium lactis, Bifidobacterium lactis plus İnülin, İnulin | Intervention Type: DIETARY_SUPPLEMENT; Name: İnulin; Assigned to Arm(s): Bifidobacterium lactis, Bifidobacterium lactis plus İnülin, Maltodextrin
C: Arm Label: Probiotics; Type: N/A; Interventions: N/A
D: Arm Label: Saccharomyces boulardii; Type: EXPERIMENTAL; Interventions: Drug: Saccharomyces boulardii | Arm Label: control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Saccharomyces boulardii; Assigned to Arm(s): Saccharomyces boulardii | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Brief Summary: The primary objective of the study was to evaluate the efficacy of lumacaftor in combination with ivacaftor at Week 24 in participants aged 12 years and older with cystic fibrosis (CF) who are homozygous for the F508del mutation on the CF transmembrane conductance regulator (CFTR) gene.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LUM 600 mg qd/IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination, Drug: Ivacaftor | Arm Label: LUM 400 mg q12h/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination | Intervention Type: DRUG; Name: Lumacaftor Plus Ivacaftor Combination; Assigned to Arm(s): LUM 400 mg q12h/ IVA 250 mg q12h, LUM 600 mg qd/IVA 250 mg q12h | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): LUM 600 mg qd/IVA 250 mg q12h | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Baseline; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Miglustat; Type: ACTIVE_COMPARATOR; Interventions: Drug: Miglustat | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Miglustat; Assigned to Arm(s): Miglustat | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: JBT101 (lenabasum) 1 mg; Type: EXPERIMENTAL; Interventions: Drug: JBT-101 (lenabasum) | Arm Label: JBT-101 (lenabasum) 5 mg; Type: EXPERIMENTAL; Interventions: Drug: JBT-101 (lenabasum) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: JBT-101 (lenabasum) 20 mg QD; Type: EXPERIMENTAL; Interventions: Drug: JBT-101 (lenabasum) | Arm Label: JBT-101 (lenabasum) 20 mg BID; Type: EXPERIMENTAL; Interventions: Drug: JBT-101 (lenabasum) | Arm Label: Placebo BID; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: JBT-101 (lenabasum); Assigned to Arm(s): JBT-101 (lenabasum) 20 mg BID, JBT-101 (lenabasum) 20 mg QD, JBT-101 (lenabasum) 5 mg, JBT101 (lenabasum) 1 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo, Placebo BID
D: Arm Label: ELX/TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: ELX/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: ELX/TEZ/IVA; Assigned to Arm(s): ELX/TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): ELX/TEZ/IVA

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Brief Summary: The primary objective of the study was to evaluate the efficacy of lumacaftor in combination with ivacaftor at Week 24 in participants aged 12 years and older with cystic fibrosis (CF) who are homozygous for the F508del mutation on the CF transmembrane conductance regulator (CFTR) gene.


Options:
A: Arm Label: Cycling in combination with Flutter® therapy; Type: EXPERIMENTAL; Interventions: Device: Flutter® | Arm Label: Cycling without Flutter® therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: No Flutter® | Intervention Type: DEVICE; Name: Flutter®; Assigned to Arm(s): Cycling in combination with Flutter® therapy | Intervention Type: DEVICE; Name: No Flutter®; Assigned to Arm(s): Cycling without Flutter® therapy
B: Intervention Type: BEHAVIORAL; Name: Supervised aerobic training; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Supervised strength training; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Unsupervised training; Assigned to Arm(s): N/A
C: Arm Label: Fitbit plus personalised text messaging & Goal Setting; Type: EXPERIMENTAL; Interventions: Other: Fitness tracker with goal setting and text message feedback | Arm Label: Fitbit Only; Type: ACTIVE_COMPARATOR; Interventions: Other: Fitness Tracker only | Intervention Type: OTHER; Name: Fitness tracker with goal setting and text message feedback; Assigned to Arm(s): Fitbit plus personalised text messaging & Goal Setting | Intervention Type: OTHER; Name: Fitness Tracker only; Assigned to Arm(s): Fitbit Only
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LUM 600 mg qd/IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination, Drug: Ivacaftor | Arm Label: LUM 400 mg q12h/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination | Intervention Type: DRUG; Name: Lumacaftor Plus Ivacaftor Combination; Assigned to Arm(s): LUM 400 mg q12h/ IVA 250 mg q12h, LUM 600 mg qd/IVA 250 mg q12h | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): LUM 600 mg qd/IVA 250 mg q12h | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Brief Summary: The primary objective of the study was to evaluate the efficacy of lumacaftor in combination with ivacaftor at Week 24 in participants aged 12 years and older with cystic fibrosis (CF) who are homozygous for the F508del mutation on the CF transmembrane conductance regulator (CFTR) gene.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 150 mg Ivacaftor q12h; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): 150 mg Ivacaftor q12h | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: VX-809, 25 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 50 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 100 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 200 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Intervention Type: DRUG; Name: VX-809; Assigned to Arm(s): VX-809, 100 mg, VX-809, 200 mg, VX-809, 25 mg, VX-809, 50 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Part A; Type: EXPERIMENTAL; Interventions: Drug: lumacaftor, Drug: ivacaftor | Arm Label: Part B; Type: EXPERIMENTAL; Interventions: Drug: lumacaftor, Drug: ivacaftor | Intervention Type: DRUG; Name: lumacaftor; Assigned to Arm(s): Part A, Part B | Intervention Type: DRUG; Name: ivacaftor; Assigned to Arm(s): Part A, Part B
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LUM 600 mg qd/IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination, Drug: Ivacaftor | Arm Label: LUM 400 mg q12h/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Lumacaftor Plus Ivacaftor Combination; Assigned to Arm(s): LUM 400 mg q12h/ IVA 250 mg q12h, LUM 600 mg qd/IVA 250 mg q12h | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): LUM 600 mg qd/IVA 250 mg q12h

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Brief Summary: The primary objective of the study was to evaluate the efficacy of lumacaftor in combination with ivacaftor at Week 24 in participants aged 12 years and older with cystic fibrosis (CF) who are homozygous for the F508del mutation on the CF transmembrane conductance regulator (CFTR) gene.


Options:
A: Arm Label: High Intensity Interval Training; Type: EXPERIMENTAL; Interventions: Other: Educational intervention, Other: Aerobic exercise | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Educational intervention | Intervention Type: OTHER; Name: Educational intervention; Assigned to Arm(s): Control Group, High Intensity Interval Training | Intervention Type: OTHER; Name: Aerobic exercise; Assigned to Arm(s): High Intensity Interval Training
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: LUM/IVA | Intervention Type: DRUG; Name: LUM/IVA; Assigned to Arm(s): LUM/IVA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LUM 600 mg qd/IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination, Drug: Ivacaftor | Arm Label: LUM 400 mg q12h/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Lumacaftor Plus Ivacaftor Combination; Assigned to Arm(s): LUM 400 mg q12h/ IVA 250 mg q12h, LUM 600 mg qd/IVA 250 mg q12h | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): LUM 600 mg qd/IVA 250 mg q12h
D: Arm Label: Fitbit plus personalised text messaging & Goal Setting; Type: EXPERIMENTAL; Interventions: Other: Fitness tracker with goal setting and text message feedback | Arm Label: Fitbit Only; Type: ACTIVE_COMPARATOR; Interventions: Other: Fitness Tracker only | Intervention Type: OTHER; Name: Fitness tracker with goal setting and text message feedback; Assigned to Arm(s): Fitbit plus personalised text messaging & Goal Setting | Intervention Type: OTHER; Name: Fitness Tracker only; Assigned to Arm(s): Fitbit Only

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Tourniquet Use During Total Knee Arthroplasty Surgery on the Postoperative Loss of Quadricepsforce
Brief Summary: The purpose for this study is to investigate the quadriceps (thigh) function preoperatively and 48 hours postoperatively during knee arthroplasty (total replacement of the knee joint) in a randomised study with or without the use of a Tourniquet (cuff around the thigh during surgery) (100 mm Hg \> systolic blood pressure).


Options:
A: Arm Label: Tourniquet; Type: EXPERIMENTAL; Interventions: Device: Tourniquet | Arm Label: No tourniquet; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Tourniquet; Assigned to Arm(s): Tourniquet
B: Arm Label: tourniquet; Type: EXPERIMENTAL; Interventions: Procedure: Total knee arthroplasty | Arm Label: non-tourniquet; Type: EXPERIMENTAL; Interventions: Procedure: Total knee arthroplasty | Intervention Type: PROCEDURE; Name: Total knee arthroplasty; Assigned to Arm(s): non-tourniquet, tourniquet
C: Arm Label: Aquamantys; Type: EXPERIMENTAL; Interventions: Device: Aquamantys | Arm Label: Standard of Care: Tourniquet; Type: ACTIVE_COMPARATOR; Interventions: Device: Tourniquet | Intervention Type: DEVICE; Name: Aquamantys; Assigned to Arm(s): Aquamantys | Intervention Type: DEVICE; Name: Tourniquet; Assigned to Arm(s): Standard of Care: Tourniquet
D: Arm Label: treatment; Type: EXPERIMENTAL; Interventions: Drug: General Anesthesia | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Neuraxial anesthesia | Intervention Type: DRUG; Name: General Anesthesia; Assigned to Arm(s): treatment | Intervention Type: DRUG; Name: Neuraxial anesthesia; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial Evaluating the Number of Passes Required for Diagnostic Cell Block During Endoscopic Ultrasound-Fine Needle Aspiration of Solid Pancreatic Mass Lesions
Brief Summary: This study will test the amount of tissue, called "cell block", obtained from your pancreas. Patients who are asked to participate in this study have a growth (mass) in the pancreas that needs a biopsy so a diagnosis can be made. Although we usually perform 2 to 4 passes (number of times the doctor biopsies the mass), at this time we do not know the ideal number of passes needed to obtain adequate amount of tissue for making a diagnosis. The purpose of this study is to compare the amount of tissue obtained with 2 passes versus 4 passes.


Options:
A: Arm Label: EUS FNA with 2 passes; Type: ACTIVE_COMPARATOR; Interventions: Procedure: EUS FNA with 2 passes | Arm Label: EUS FNA with 4 passes; Type: ACTIVE_COMPARATOR; Interventions: Procedure: EUS FNA with 4 passes | Intervention Type: PROCEDURE; Name: EUS FNA with 2 passes; Assigned to Arm(s): EUS FNA with 2 passes | Intervention Type: PROCEDURE; Name: EUS FNA with 4 passes; Assigned to Arm(s): EUS FNA with 4 passes
B: Arm Label: Lymph nodes, pancreatic masses & cysts; Type: OTHER; Interventions: Procedure: EUS-FNA, Device: nCLE | Intervention Type: PROCEDURE; Name: EUS-FNA; Assigned to Arm(s): Lymph nodes, pancreatic masses & cysts | Intervention Type: DEVICE; Name: nCLE; Assigned to Arm(s): Lymph nodes, pancreatic masses & cysts
C: Arm Label: 22G ProCore biopsy needle; Type: ACTIVE_COMPARATOR; Interventions: Procedure: 22G ProCore biopsy needle | Arm Label: 22G standard FNA needle; Type: ACTIVE_COMPARATOR; Interventions: Procedure: 22G standard FNA needle | Intervention Type: PROCEDURE; Name: 22G ProCore biopsy needle; Assigned to Arm(s): 22G ProCore biopsy needle | Intervention Type: PROCEDURE; Name: 22G standard FNA needle; Assigned to Arm(s): 22G standard FNA needle
D: Arm Label: 1.EUS-FNA with or without suction; Type: EXPERIMENTAL; Interventions: Procedure: 1.EUS-FNA with or without suction | Arm Label: 2.Pushing the stylet or injecting air; Type: EXPERIMENTAL; Interventions: Procedure: 2.Pushing the stylet or injecting air | Intervention Type: PROCEDURE; Name: 1.EUS-FNA with or without suction; Assigned to Arm(s): 1.EUS-FNA with or without suction | Intervention Type: PROCEDURE; Name: 2.Pushing the stylet or injecting air; Assigned to Arm(s): 2.Pushing the stylet or injecting air

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Placebo-controlled Trial With Vitamin D to Prevent Worsening/Relieve Aromatase Inhibitor-induced Musculoskeletal Symptoms in Breast Cancer Patients
Brief Summary: The third generation oral aromatase inhibitors (AIs) are increasingly being used in the management of estrogen receptor positive breast cancer. One of the issues related with administration of oral AIs is their side effects, particularly on the musculoskeletal system. Although the prevalence and importance of arthralgia and myalgia occurring in BC patients receiving adjuvant AIs are evident, the mechanisms clearly explaining these invalidating symptoms are unknown.

In this project, we aim to unravel the interaction between vitamin D and musculoskeletal adverse events experienced by AI users. We will also evaluate how vitamin D supplementation affects AI-induced musculoskeletal symptoms in breast cancer patients, by means of a randomized placebo-controlled double blind clinical trial. We will assess changes in the musculoskeletal system by using magnetic resonance imaging of joints, hand grip strength and also monitor serum IGF-I and estrogen levels together with bone resorption and formation markers.


Options:
A: Arm Label: vitamin D3; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): vitamin D3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Questioners | Arm Label: B; Type: EXPERIMENTAL; Interventions: Behavioral: STAR website | Intervention Type: BEHAVIORAL; Name: Questioners; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: STAR website; Assigned to Arm(s): B
C: Intervention Type: OTHER; Name: aromatase inhibition therapy - OBSERVATIONAL ONLY; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: medical chart review; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: assessment of therapy complications; Assigned to Arm(s): N/A
D: Arm Label: Vitamin D3 4000 IU; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D3 | Arm Label: Vitamin D3 600 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D3 | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Vitamin D3 4000 IU | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Vitamin D3 600 IU

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimizing Outcomes in Women With Gestational Diabetes Mellitus and Their Infants
Brief Summary: The purpose of this study is to determine whether a 14 week intervention is successful in improving outcomes for women with gestational diabetes mellitus and their infants.


Options:
A: Arm Label: Entree energy density 100%; Type: EXPERIMENTAL; Interventions: Other: Energy density feeding study | Arm Label: Entree energy density 85%; Type: EXPERIMENTAL; Interventions: Other: Energy density feeding study | Arm Label: Entree energy density 75%; Type: EXPERIMENTAL; Interventions: Other: Energy density feeding study | Intervention Type: OTHER; Name: Energy density feeding study; Assigned to Arm(s): Entree energy density 100%, Entree energy density 75%, Entree energy density 85%
B: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: Wait-listed control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): intervention
C: Arm Label: parent-targeted intervention; Type: EXPERIMENTAL; Interventions: Behavioral: multi-component/setting parent-targeted intervention | Arm Label: Primary Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: multi-component/setting parent-targeted intervention; Assigned to Arm(s): parent-targeted intervention
D: Arm Label: 1M0.5; Type: EXPERIMENTAL; Interventions: Other: Timing of Diet and Flavor Experience | Arm Label: 1M1.5; Type: EXPERIMENTAL; Interventions: Other: Timing of Diet and Flavor Experience | Arm Label: 3M0.5; Type: EXPERIMENTAL; Interventions: Other: Timing of Diet and Flavor Experience | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Timing of Diet and Flavor Experience; Assigned to Arm(s): 1M0.5, 1M1.5, 3M0.5

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimizing Outcomes in Women With Gestational Diabetes Mellitus and Their Infants
Brief Summary: The purpose of this study is to determine whether a 14 week intervention is successful in improving outcomes for women with gestational diabetes mellitus and their infants.


Options:
A: Arm Label: National Vaccine Program Plus Radio; Type: EXPERIMENTAL; Interventions: Behavioral: Appropriate complementary feeding messages | Arm Label: Comparison (no intervention); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Appropriate complementary feeding messages; Assigned to Arm(s): National Vaccine Program Plus Radio
B: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Other: Childhood Obesity | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Childhood Obesity; Assigned to Arm(s): Treatment
C: Intervention Type: BEHAVIORAL; Name: Promotion of a healthy diet and physical activity; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Avoidance of Alcohol, Drugs, and Tobacco; Assigned to Arm(s): N/A
D: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: Wait-listed control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): intervention

Answer: D